Europe Lung Cancer Therapeutics Market Growth, Size, Trends, Share, Revenue and Future Outlook: SPER Market Research

Q: How can I get a sample report on the Europe Lung Cancer Therapeutics Market?

You can get the sample pages by clicking the link - Click Here

Published: Apr 2024	Report ID: HLCA2446	Pages: 1 - 155	Formats^*:
Category : Healthcare

Europe Lung Cancer Therapeutics Market Introduction and Overview

According to SPER Market Research, the Europe Lung Cancer Therapeutics Market is estimated to reach USD 4.05 Billion by 2033 with a CAGR of 7.3%.

The report includes an in-depth analysis of the Europe Lung Cancer Therapeutics Market, including market size and trends, product mix, applications, and supplier analysis. Lung cancer is a form of cancer that impairs the ability of the lungs to supply oxygen to the blood. It is one of the most frequent types of cancer, with a significant fatality rate. Lung cancer is defined as the uncontrolled development of cells in the lungs. The leading causes of lung cancer include cigarette smoking, asbestos exposure, and smoking cigars. This illness is distinguished by weight loss, shortness of breath, cough, and chest pain. Lung cancer is also known as lung carcinoma.

Market Opportunities and Challenges

The rising prevalence of lung cancer and growing need for tailored therapies, as well as the availability of highly effective medications, are the primary factors influencing the growth of the lung cancer therapeutics market. Furthermore, environmental pollution, smoking, reimbursements, and an increase in health insurance premiums are the factors that will accelerate the market's growth rate. Furthermore, the increased use of early detection and the growing elderly population will moderate the growth rate of the lung cancer therapies market.

Furthermore, increased R&D activities, the launch of nanomedicines for the treatment of lung cancer, and rising approvals in lung cancer therapies will all contribute to market expansion. However, the availability of generic medications, the high cost of treatment, and the side effects associated with radiation and chemotherapy all operate as market limitations, impeding market expansion. Poor cancer diagnostic facilities and a shortage of competent personnel will exacerbate the lung cancer therapies industry.

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape

The lung cancer therapies industry is extremely competitive, with numerous pharmaceutical companies fighting for market share. Multinational corporations and smaller oncology-focused biotechnology enterprises are among the market's key players. These companies prioritise research and development in order to bring novel cures to market. Strategic collaborations, mergers, and acquisitions are frequent methods used by market participants to extend their product line and global reach. The major key players in the Europe Lung Cancer Therapeutics Market are: Allergan, Amgen Inc, Dr. Reddyâ€™s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Others.

Scope of the Report:

Report Metric	Details
Market size available for years	2020-2033
Base year considered	2023
Forecast period	2024-2033
Segments covered	By Cancer Type, By Molecule Type, By Treatment Type, By Therapy Type, By End User
Regions covered	Belgium, France, Germany, Italy, Netherlands, Russia, Spain, Switzerland, The U.K., Turkey, Rest of Europe
Companies Covered	Allergan, Amgen Inc, Dr. Reddyâ€™s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Others.

COVID-19 Impact on Europe Lung Cancer Therapeutics Market

The COVID-19 pandemic has had a substantial influence on the European lung cancer medicines industry. Delays in detection and treatment owing to reallocation of healthcare resources and patient unwillingness to seek medical care have resulted in fewer lung cancer diagnoses and subsequent treatment initiations. Furthermore, disruptions in drug manufacturing and supply chains have hampered the availability of lung cancer treatments. Clinical studies for new therapies have also been halted, limiting the development of revolutionary treatments. However, telemedicine acceptance has expanded, allowing for remote patient consultations and monitoring. Despite these obstacles, attempts to resume routine healthcare services and intensify immunisation campaigns are expected to slowly restore market stability.

Key Target Audience:

Pharmaceutical Companies
Biotechnology Companies
Medical Device Manufacturers
Research Institutions
Academic Institutions
Healthcare Providers
Regulatory Authorities
Patients and Patient Advocacy Groups
Investors and Financial Institutions
Others

Our in-depth analysis of the Europe Lung Cancer Therapeutics Market includes the following segments:

By Cancer Type:	Chest Wall Tumors Mediastinal Tumors Mesothelioma Metastatic Lung Cancer Non-Small Cell Lung Cancer Pulmonary Neuroendocrine Tumors
By Molecule Type:	Biologics Small Molecules
By Treatment Type:	Chemotherapy Immunotherapy Radiation Therapy Targeted Therapy Others
By Therapy Type:	Combination Therapy Single Drug Therapy
By End User:	Homecare Hospitals Speciality Clinics Others

Key Topics Covered in the Report:

Europe Lung Cancer Therapeutics Market Size (FYâ€™2024-FYâ€™2033)
Overview of Europe Lung Cancer Therapeutics Market
Segmentation of Europe Lung Cancer Therapeutics Market By Cancer Type (Chest Wall Tumors, Mediastinal Tumors, Mesothelioma, Metastatic Lung Cancer, Non-Small Cell Lung Cancer, Pulmonary Neuroendocrine Tumors)
Segmentation of Europe Lung Cancer Therapeutics Market By Molecule Type (Biologics, Small Molecules)
Segmentation of Europe Lung Cancer Therapeutics Market By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Others)
Segmentation of Europe Lung Cancer Therapeutics Market By Therapy Type (Combination Therapy, Single Drug Therapy)
Segmentation of Europe Lung Cancer Therapeutics Market By End User (Homecare, Hospitals, Speciality Clinics, Others)
Statistical Snap of Europe Lung Cancer Therapeutics Market
Expansion Analysis of Europe Lung Cancer Therapeutics Market
Problems and Obstacles in Europe Lung Cancer Therapeutics Market
Competitive Landscape in the Europe Lung Cancer Therapeutics Market
Impact of COVID-19 and Demonetization on Europe Lung Cancer Therapeutics Market
Details on Current Investment in Europe Lung Cancer Therapeutics Market
Competitive Analysis of Europe Lung Cancer Therapeutics Market
Prominent Players in the Europe Lung Cancer Therapeutics Market
SWOT Analysis of Europe Lung Cancer Therapeutics Market
Europe Lung Cancer Therapeutics Market Future Outlook and Projections (FYâ€™2024-FYâ€™2033)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERâ€™s internal database
2.1.4. Premium insight from KOLâ€™s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Lung Cancer Therapeutics Market

5. Market variable and outlook

5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERâ€™s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Europe Lung Cancer Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Lung Cancer Therapeutics Market

7. Europe Lung Cancer Therapeutics Market, By Cancer Type (USD Million) 2020-2033

7.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Cancer Type, 2020-2026
7.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Cancer Type, 2027-2033
7.3. Chest Wall Tumors
7.4. Mediastinal Tumors
7.5. Mesothelioma
7.6. Metastatic Lung Cancer
7.7. Non-Small Cell Lung Cancer
7.8. Pulmonary Neuroendocrine Tumors

8. Europe Lung Cancer Therapeutics Market, By Molecule Type (USD Million) 2020-2033

8.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Molecule Type, 2020-2026
8.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Molecule Type, 2027-2033
8.3. Biologics
8.4. Small Molecules

9. Europe Lung Cancer Therapeutics Market, By Treatment Type (USD Million) 2020-2033

9.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Treatment Type, 2020-2026
9.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Treatment Type, 2027-2033
9.3. Chemotherapy
9.4. Immunotherapy
9.5. Radiation Therapy
9.6. Targeted Therapy
9.7. Others

10. Europe Lung Cancer Therapeutics Market, By Therapy Type (USD Million) 2020-2033

10.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Therapy Type, 2020-2026
10.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By Therapy Type, 2027-2033
10.3. Combination Therapy
10.4. Single Drug Therapy

11. Europe Lung Cancer Therapeutics Market, By End User (USD Million) 2020-2033

11.1. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By End User, 2020-2026
11.2. Europe Lung Cancer Therapeutics Market Size, Share and Forecast, By End User, 2027-2033
11.3. Homecare
11.4. Hospitals
11.5. Speciality Clinics
11.6. Others

12. Europe Lung Cancer Therapeutics Market Forecast, 2020-2033 (USD Million)

12.1. Europe Lung Cancer Therapeutics Market Size and Market Share

13. Europe Lung Cancer Therapeutics Market, By Region, 2020-2033 (USD Million)

13.1. Europe Lung Cancer Therapeutics Market Size and Market Share By Region (2020-2026)
13.2. Europe Lung Cancer Therapeutics Market Size and Market Share By Region (2027-2033)
13.3. Belgium
13.4. France
13.5. Germany
13.6. Italy
13.7. Netherlands
13.8. Russia
13.9. Spain
13.10. Switzerland
13.11. The U.K.
13.12. Turkey
13.13. Rest of Europe

14. Company Profile

14.1. Allergan
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Amgen Inc
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Dr. Reddyâ€™s Laboratories Ltd
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. GlaxoSmithKline plc
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Johnson & Johnson Private Limited
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Merck Sharp & Dohme Corp
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Novartis AG
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Pfizer Inc
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Sun Pharmaceutical Industries Ltd
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Takeda Pharmaceutical Company Limited
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Teva Pharmaceutical Industries Ltd.
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. Others

15. List of Abbreviations

16. Reference Links

17. Conclusion

18. Research Scope

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is the Europe Lung Cancer Therapeutics Market?

Europe Lung Cancer Therapeutics Market is projected to reach USD 4.05 billion by 2033, growing at a CAGR of 7.3% during the forecast period.

What is the growth rate of the Europe Lung Cancer Therapeutics Market?

Europe Lung Cancer Therapeutics Market grew in Market size from 2022. The Market is expected to reach USD 4.05 billion by 2033, at a CAGR of 7.3% during the forecast period.

What is the anticipated CAGR of the Europe Lung Cancer Therapeutics Market?

Europe Lung Cancer Therapeutics Market CAGR of 7.3% during the forecast period.

How can I get a sample report on the Europe Lung Cancer Therapeutics Market?

You can get the sample pages by clicking the link - Click Here

What is the Market size of the Europe Lung Cancer Therapeutics Market?

Europe Lung Cancer Therapeutics Market size is USD 4.05 billion from 2024 to 2033.

Which segment is expected to Europe Lung Cancer Therapeutics Market?

Europe Lung Cancer Therapeutics Market Segment is covered By Cancer Type, By Molecule Type, By Treatment Type, By Therapy Type, By End User.

Which region is expected to have the highest Market share in the Europe Lung Cancer Therapeutics Market?

The Europe is anticipated to have the highest Market share in the Europe Lung Cancer Therapeutics Market.

Who are the key players in Europe Lung Cancer Therapeutics Market?

The key players in the Market include Companies Covered Allergan, Amgen Inc, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck Sharp & Dohme Corp, Teva Pharmaceutical Industries Ltd., Others.

What is the conclusion of the Europe Lung Cancer Therapeutics Market?

It is one of the most frequent types of cancer, with a significant fatality rate. Lung cancer is defined as the uncontrolled development of cells in the lungs.